Skin Diseases, Eczematous News - LARVOL Sigma

Skin Diseases, Eczematous

Welcome, Profile Billing Logout

71 Mechanisms of Action

«1 2 3 4 5 6 789 10 »

||||||||||  Stelara (ustekinumab) / J&J
Clinical:  Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) -  Mar 10, 2013
P2, N=32, Recruiting,  Sponsor: Rockefeller University
Not yet recruiting --> Recruiting

|||||||||| Trial initiation date: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Mar 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Recruiting Initiation date: Feb 2013 --> Oct 2013

||||||||||  pegcantratinib (SNA-120) / Sienna
New P2 trial:  A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (clinicaltrials.gov) -  Mar 7, 2013
P2, N=210, Recruiting,  Sponsor: Creabilis SA

||||||||||  Stelara (ustekinumab) / J&J
New P2 trial:  Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis (clinicaltrials.gov) -  Mar 5, 2013
P2, N=32, Recruiting,  Sponsor: Rockefeller University

|||||||||| Trial withdrawal: PREAII: Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents (clinicaltrials.gov) - Feb 25, 2013
P3, N=0, Withdrawn, Sponsor: Allerderm
Initiation date: Feb 2013 --> Oct 2013 Recruiting --> Withdrawn

|||||||||| Enrollment change: PREAII: Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents (clinicaltrials.gov) - Feb 25, 2013
P3, N=0, Withdrawn, Sponsor: Allerderm
Recruiting --> Withdrawn N=100 --> 0

|||||||||| Enrollment change: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Feb 21, 2013
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.
N=100 --> 0 N=200 --> 263

|||||||||| Trial completion: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Feb 21, 2013
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.
N=200 --> 263 Active, not recruiting --> Completed

||||||||||  Desonate (desonide gel) / LEO Pharma
Trial completion:  Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (clinicaltrials.gov) -  Feb 19, 2013
P3, N=251, Completed,  Sponsor: Pierre Fabre Medicament
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Photofrin (porfimer sodium) / Advanz Pharma
Trial initiation date:  Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light (clinicaltrials.gov) -  Feb 17, 2013
P2, N=0, Withdrawn,  Sponsor: Pinnacle Biologics Inc.
Active, not recruiting --> Completed Initiation date: Jul 2012 --> May 2013

||||||||||  Zalain (sertaconazole) / Elder Pharma
New P2 trial:  Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis (clinicaltrials.gov) -  Feb 13, 2013
P2, N=80, Recruiting,  Sponsor: Spirig Pharma Ltd.

|||||||||| Trial termination: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=2, Terminated, Sponsor: Cosmetique Active International
Initiation date: Jul 2012 --> May 2013 Recruiting --> Terminated; Sponsor Decision

|||||||||| Enrollment change: Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis (clinicaltrials.gov) - Feb 11, 2013
P=N/A, N=2, Terminated, Sponsor: Cosmetique Active International
Recruiting --> Terminated; Sponsor Decision N=460 --> 2

||||||||||  tacrolimus XR / Generic mfg.
New P2 trial:  Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients (clinicaltrials.gov) -  Feb 10, 2013
P2, N=10, Recruiting,  Sponsor: UMC Utrecht

||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion:  Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) (clinicaltrials.gov) -  Feb 5, 2013
P2, N=31, Completed,  Sponsor: Regeneron Pharmaceuticals
N=460 --> 2 Active, not recruiting --> Completed

||||||||||  fevipiprant (QAW039) / Novartis
New P2 trial:  Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) -  Feb 5, 2013
P2, N=92, Recruiting,  Sponsor: Novartis Pharmaceuticals

|||||||||| Enrollment change: The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) (clinicaltrials.gov) - Feb 4, 2013
P=N/A, N=65, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=130 --> 65

|||||||||| Trial termination: Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients (clinicaltrials.gov) - Jan 31, 2013
P3, N=30, Terminated, Sponsor: Hordinsky, Maria K., MD
N=130 --> 65 Suspended --> Terminated; IRB approval has lapsed.

||||||||||  tacrolimus topical / Generic mfg.
New P4 trial:  An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis (clinicaltrials.gov) -  Jan 31, 2013
P4, N=30, Completed,  Sponsor: Janssen-Cilag Ltd.,Thailand

|||||||||| New P3 trial: Emollients in the Management of Atopic Dermatitis (clinicaltrials.gov) - Jan 28, 2013
P3, N=347, Completed, Sponsor: Pierre Fabre Medicament

|||||||||| Trial completion: A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis (clinicaltrials.gov) - Jan 27, 2013
P4, N=20, Completed, Sponsor: Wake Forest School of Medicine
Suspended --> Terminated; IRB approval has lapsed. Active, not recruiting --> Completed

||||||||||  LEO 29102 / LEO Pharma
Enrollment change:  Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) -  Jan 24, 2013
P1, N=102, Completed,  Sponsor: LEO Pharma
Active, not recruiting --> Completed N=72 --> 102

||||||||||  LEO 29102 / LEO Pharma
Trial completion:  Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) -  Jan 24, 2013
P1, N=102, Completed,  Sponsor: LEO Pharma
N=72 --> 102 Recruiting --> Completed

||||||||||  fluticasone / Generic mfg.
New P3 trial:  Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children (clinicaltrials.gov) -  Jan 17, 2013
P3, N=100, Recruiting,  Sponsor: Elena Rubio Gomis

|||||||||| Trial initiation date: PREAII: Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents (clinicaltrials.gov) - Jan 15, 2013
P3, N=0, Withdrawn, Sponsor: Allerderm
Recruiting --> Completed Initiation date: May 2012 --> Dec 2012

|||||||||| Trial completion: Safety and Efficacy Study in Subjects With Seborrheic Dermatitis (clinicaltrials.gov) - Jan 6, 2013
P2, N=240, Completed, Sponsor: Medicis Global Service Corporation
Initiation date: May 2012 --> Dec 2012 Recruiting --> Completed

||||||||||  MK-8226 / Merck (MSD)
Enrollment open:  A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) -  Jan 1, 2013
P1, N=170, Recruiting,  Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Enrollment closed, IO biomarker: 2ndDermisII: Efficacy and Safety of a a Biofunctional Textile in the Management of Atopic Dermatitis (clinicaltrials.gov) - Dec 18, 2012
P2, N=100, Active, not recruiting, Sponsor: Universidade do Porto
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

|||||||||| Enrollment change: Cooling Pillow for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=9, Completed, Sponsor: Northwestern University
Recruiting --> Active, not recruiting N=20 --> 9

|||||||||| Trial completion: Cooling Pillow for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=9, Completed, Sponsor: Northwestern University
N=20 --> 9 Recruiting --> Completed

|||||||||| Trial completion: Acupressure in Pruritus for Atopic Dermatitis (clinicaltrials.gov) - Dec 9, 2012
P=N/A, N=15, Completed, Sponsor: Northwestern University
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  tacrolimus topical / Generic mfg.
New P4 trial:  Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis (clinicaltrials.gov) -  Dec 6, 2012
P4, N=120, Recruiting,  Sponsor: Astellas Pharma China, Inc.

|||||||||| Enrollment change: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed N=100 --> 35

|||||||||| Trial completion: Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=35, Completed, Sponsor: Northwestern University
N=100 --> 35 Active, not recruiting --> Completed

|||||||||| Enrollment change, Adherence: Text Messaging and Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=26, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed N=60 --> 26

|||||||||| Trial completion, Adherence: Text Messaging and Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2012
P=N/A, N=26, Completed, Sponsor: Northwestern University
N=60 --> 26 Recruiting --> Completed

||||||||||  Fluzone (influenza vaccine) / Sanofi, Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion:  Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot (clinicaltrials.gov) -  Nov 27, 2012
P0, N=40, Completed,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Completed

||||||||||  MK-8226 / Merck (MSD)
New P1 trial:  A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) (clinicaltrials.gov) -  Nov 20, 2012
P1, N=170, Recruiting,  Sponsor: Merck Sharp & Dohme Corp.

||||||||||  Eucrisa (crisaborole) / Pfizer
Trial completion:  Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis (clinicaltrials.gov) -  Nov 14, 2012
P1/2, N=23, Completed,  Sponsor: Anacor Pharmaceuticals, Inc.
Recruiting --> Completed Recruiting --> Completed

||||||||||  mapracorat (BOL-303242-X) / Bayer
Enrollment change:  HPA Axis Study in Adults (clinicaltrials.gov) -  Oct 21, 2012
P2, N=23, Completed,  Sponsor: Bayer
Recruiting --> Completed N=30 --> 23

||||||||||  mapracorat (BOL-303242-X) / Bayer
Trial completion:  HPA Axis Study in Adults (clinicaltrials.gov) -  Oct 21, 2012
P2, N=23, Completed,  Sponsor: Bayer
N=30 --> 23 Active, not recruiting --> Completed

||||||||||  SB-705498 / GSK
Enrollment change:  Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) -  Oct 10, 2012
P1, N=16, Completed,  Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=20 --> 16

||||||||||  SB-705498 / GSK
Trial completion:  Investigation of Topical SB705498 on Healthy Volunteers (clinicaltrials.gov) -  Oct 10, 2012
P1, N=16, Completed,  Sponsor: GlaxoSmithKline
N=20 --> 16 Recruiting --> Completed

|||||||||| New P2 trial: Safety and Efficacy Study in Subjects With Seborrheic Dermatitis (clinicaltrials.gov) - Oct 9, 2012
P2, N=240, Completed, Sponsor: Medicis Global Service Corporation

||||||||||  difamilast (MM36) / Otsuka, Medimetriks
New P1 trial:  A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis (clinicaltrials.gov) -  Oct 3, 2012
P1, N=92, Completed,  Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion:  Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis (clinicaltrials.gov) -  Oct 1, 2012
P1, N=30, Completed,  Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P2 trial: Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (clinicaltrials.gov) - Sep 19, 2012
P2, N=263, Completed, Sponsor: Amphastar Pharmaceuticals, Inc.

|||||||||| Enrollment open: The Effect of Medical Clowns and Topical Anesthetic Cream on Pain and Anxiety in Children Undergoing Allergy Skin Tests (clinicaltrials.gov) - Sep 18, 2012
P=N/A, N=160, Recruiting, Sponsor: Meir Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P3 trial:  A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis (clinicaltrials.gov) -  Sep 5, 2012
P3, N=50, Recruiting,  Sponsor: Mitsubishi Tanabe Pharma Corporation

||||||||||  Xolair (omalizumab) / Roche, Novartis
New P1 trial:  OXAD: Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis (clinicaltrials.gov) -  Aug 30, 2012
P1, N=8, Completed,  Sponsor: Stanford University